Trial Profile
A Phase 1b/2, Open-Label, Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 13 Jul 2023
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Tivozanib (Primary)
- Indications Liver cancer
- Focus Adverse reactions
- Acronyms DEDUCTIVE
- Sponsors AVEO Oncology
- 10 Jul 2023 Status changed from active, no longer recruiting to discontinued.
- 21 Jan 2023 The protocol was amended in 2021 to include a cohort of patients previously treated with atezolizumab and bevacizumab (cohort B).
- 21 Jan 2023 Results presented at the 2023 Gastrointestinal Cancers Symposium